Latest Conference Articles

September 10th 2021, 9:23pm

International Myeloma Society Annual Meeting

Larry Anderson, MD, PhD, discusses outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma, as demonstrated in the phase 2 KarMMa trial.

September 10th 2021, 9:15pm

American Urological Association Annual Meeting

Bacille Calmette-Guérin (BCG) plus N-803 yielded promising responses and an encouraging safety profile in patients with BCG-unresponsive, non-muscle invasive bladder cancer carcinoma in situ.

September 10th 2021, 9:02pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Brad S. Kahl, MD, discusses the potential utility of BTK inhibitor–based combinations in the frontline setting of mantle cell lymphoma.

September 10th 2021, 8:53pm

American Urological Association Annual Meeting

Patients with nonmetastatic castration-resistant prostate cancer demonstrated high adherence rates and favorable prostate-specific antigen response to apalutamide according to real-world evidence presented at the 2021 American Urological Association Annual Meeting.

September 10th 2021, 8:48pm

American Urological Association Annual Meeting

Antibody titers and fold changes may prove to be a prognostic marker for the efficacy of nadofaragene firadenovec for the treatment of patients with bacillus Calmette-Guérun unresponsive non-muscle invasive bladder cancer.

September 10th 2021, 8:31pm

IASLC World Conference on Lung Cancer

Atezolizumab plus carboplatin and pemetrexed yielded a favorable safety and efficacy profile in patients with advanced non-squamous non-small cell lung cancer with untreated brain metastases.

September 10th 2021, 8:29pm

International Myeloma Society Annual Meeting

Elranatamab elicited encouraging responses with a manageable toxicity profile when used alone or in combination with lenalidomide in patients with relapsed/refractory multiple myeloma, with efficacy observed even in those who received prior BCMA-directed therapy or who were triple-class refractory, according to data from the phase 1 MagnetisMM-1 trial.

September 10th 2021, 8:00pm

Society of Hematologic Oncology Annual Meeting (SOHO)

CAR T-cell products targeting CD19 are eliciting clinical activity in patients with indolent non-Hodgkin lymphoma, as seen in the ZUMA-5, SCHOLAR-5, and ELARA trials, but longer follow-up will showcase the true potential of this treatment in this subpopulation.

September 10th 2021, 7:57pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Treatment with fixed-duration rituximab plus the chemotherapy bendamustine was associated with more favorable outcomes than the triplet of dexamethasone, rituximab, and cyclophosphamide, as well as bortezomib, dexamethasone, and rituximab in patients with treatment-naïve Waldenström macroglobulinemia.

September 10th 2021, 6:57pm

Society of Hematologic Oncology Annual Meeting (SOHO)

A single dose of ciltacabtagene autoleucel continued to elicit early, deep, and durable responses and showcase a manageable safety profile in heavily pretreated patients with multiple myeloma.

September 10th 2021, 6:53pm

International Myeloma Society Annual Meeting

The CAR T-cell therapy ciltacabtagene autoleucel has emerged as a potentially durable treatment strategy for patients with relapsed/refractory multiple myeloma who have progressed on 1 to 3 prior lines of treatment and are refractory to lenalidomide.

September 10th 2021, 6:31pm

International Myeloma Society Annual Meeting

Idecabtagene vicleucel continued to elicit frequent, deep, and durable responses among patients with heavily pretreated relapsed/refractory multiple myeloma irrespective of whether patients received 3 or at least 4 prior therapies.

September 10th 2021, 5:41pm

International Myeloma Society Annual Meeting

Talquetamab, an off-the-shelf T-cell redirecting, GP3C5D-targeting agent, has continued to show promising clinical activity in patients with relapsed/refractory multiple myeloma, especially when given at the recommended phase 2 dose of 405 µg/kg weekly in subcutaneous formulation.

September 10th 2021, 5:03pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Treating patients with accelerated phase myeloproliferative neoplasm is an ongoing therapeutic challenge, due to the lack of standard treatment approaches, according to an expert.

September 10th 2021, 2:41pm

International Myeloma Society Annual Meeting

Vaishali Sanchorawala, MD, discusses the impact of renal and cardiac response on survival in patients with light chain amyloidosis. 

September 10th 2021, 12:04pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Srdan Verstovsek, MD, PhD, discusses ongoing research in myelofibrosis-related anemia.

September 9th 2021, 9:45pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Historical prognostic markers for chemoimmunotherapy have largely lost their clinically relevance in the context of targeted therapies for patients with chronic lymphocytic leukemia; however, IGHV and TP53 mutational status remain important predictive markers of response, now for novel treatments.

September 9th 2021, 9:06pm

IASLC World Conference on Lung Cancer

The combination of lurbinectedin and doxorubicin produced comparable efficacy to that of standard-of-care vincristine, cyclophosphamide, and doxorubicin or topotecan in patients with relapsed small cell lung cancer, missing the primary end point of the phase 3 ATLANTIS trial.

September 9th 2021, 9:00pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Sitting at the forefront of clinical development, pirtobrutinib and lisocabtagene maraleucel have generated significant enthusiasm in chronic lymphocytic leukemia.

September 9th 2021, 8:56pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Patients with chronic lymphocytic leukemia are at an increased risk for infection whether they are in the premalignant state of monoclonal B lymphocytosis, during active surveillance for those are treatment naïve, or are on active treatment.